400 related articles for article (PubMed ID: 23873327)
61. Measuring antianginal drug efficacy using exercise testing for chronic angina: improved exercise performance with ranolazine, a pFOX inhibitor.
Chaitman BR
Curr Probl Cardiol; 2002 Dec; 27(12):527-55. PubMed ID: 12501118
[No Abstract] [Full Text] [Related]
62. Ranolazine: a review of its use in chronic stable angina pectoris.
Keating GM
Drugs; 2008; 68(17):2483-503. PubMed ID: 19016575
[TBL] [Abstract][Full Text] [Related]
63. Novel therapeutic approaches to treating chronic angina in the setting of chronic ischemic heart disease.
Chaitman BR; Sano J
Clin Cardiol; 2007 Feb; 30(2 Suppl 1):I25-30. PubMed ID: 18373327
[TBL] [Abstract][Full Text] [Related]
64. Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial.
Weisz G; Farzaneh-Far R; Ben-Yehuda O; Debruyne B; Montalescot G; Lerman A; Mahmud E; Alexander KP; Ohman EM; White HD; Olmsted A; Walker GA; Stone GW
Am Heart J; 2013 Dec; 166(6):953-959.e3. PubMed ID: 24268208
[TBL] [Abstract][Full Text] [Related]
65. Ranolazine: an anti-anginal drug with further therapeutic potential.
Reffelmann T; Kloner RA
Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):319-29. PubMed ID: 20222810
[TBL] [Abstract][Full Text] [Related]
66. Ranolazine: focusing on angina pectoris.
McCullough PA
Drugs Today (Barc); 2006 Mar; 42(3):177-83. PubMed ID: 16628259
[TBL] [Abstract][Full Text] [Related]
67. Extended-release ranolazine: critical evaluation of its use in stable angina.
Truffa AA; Newby LK; Melloni C
Vasc Health Risk Manag; 2011; 7():535-9. PubMed ID: 21915171
[TBL] [Abstract][Full Text] [Related]
68. Ranolazine: a review of its use in chronic stable angina pectoris.
Siddiqui MA; Keam SJ
Drugs; 2006; 66(5):693-710. PubMed ID: 16620147
[TBL] [Abstract][Full Text] [Related]
69. Extracorporeal shockwave myocardial revascularization improves clinical symptoms and left ventricular function in patients with refractory angina.
Zuozienė G; Laucevičius A; Leibowitz D
Coron Artery Dis; 2012 Jan; 23(1):62-7. PubMed ID: 22107803
[TBL] [Abstract][Full Text] [Related]
70. Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis.
Savarese G; Rosano G; D'Amore C; Musella F; Della Ratta GL; Pellegrino AM; Formisano T; Vitagliano A; Cirillo A; Cice G; Fimiani L; del Guercio L; Trimarco B; Perrone-Filardi P
Int J Cardiol; 2013 Nov; 169(4):262-70. PubMed ID: 24063912
[TBL] [Abstract][Full Text] [Related]
71. Ranolazine: new approach for the treatment of stable angina pectoris.
Stanley WC
Expert Rev Cardiovasc Ther; 2005 Sep; 3(5):821-9. PubMed ID: 16181027
[TBL] [Abstract][Full Text] [Related]
72. Management of chronic stable angina pectoris.
Rodríguez-Ospina L; Montano-Soto L
Bol Asoc Med P R; 2008; 100(4):39-47. PubMed ID: 19400528
[TBL] [Abstract][Full Text] [Related]
73. New Anti-Anginal Drugs: Ranolazine.
Cavallino C; Facchini M; Veia A; Bacchni S; Rosso R; Rognoni A; Rametta F; Lupi A; Bongo AS
Cardiovasc Hematol Agents Med Chem; 2015; 13(1):14-20. PubMed ID: 25544118
[TBL] [Abstract][Full Text] [Related]
74. Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial.
Alexander KP; Weisz G; Prather K; James S; Mark DB; Anstrom KJ; Davidson-Ray L; Witkowski A; Mulkay AJ; Osmukhina A; Farzaneh-Far R; Ben-Yehuda O; Stone GW; Ohman EM
Circulation; 2016 Jan; 133(1):39-47. PubMed ID: 26555329
[TBL] [Abstract][Full Text] [Related]
75. Ranolazine: a potential new treatment for chronic stable angina.
Anderson JR; Khou S; Nawarskas JJ
Heart Dis; 2001; 3(4):263-9. PubMed ID: 11975803
[TBL] [Abstract][Full Text] [Related]
76. Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial.
Arnold SV; Morrow DA; Wang K; Lei Y; Mahoney EM; Scirica BM; Braunwald E; Cohen DJ;
Circ Cardiovasc Qual Outcomes; 2008 Nov; 1(2):107-15. PubMed ID: 20031797
[TBL] [Abstract][Full Text] [Related]
77. Clinical and Economic Outcomes of Ranolazine Versus Conventional Antianginals Users Among Veterans With Chronic Stable Angina Pectoris.
Bress AP; Dodson JA; King JB; Sauer BC; Reese T; Crook J; Radwanski P; Knippenberg K; Greene T; Nelson RE; Munger MA; Weintraub WS; LaFleur J
Am J Cardiol; 2018 Dec; 122(11):1809-1816. PubMed ID: 30292334
[TBL] [Abstract][Full Text] [Related]
78. Conventional and novel drug therapeutics to relief myocardial ischemia.
Dvir D; Battler A
Cardiovasc Drugs Ther; 2010 Aug; 24(4):319-23. PubMed ID: 20658184
[TBL] [Abstract][Full Text] [Related]
79. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial.
Scirica BM; Morrow DA; Hod H; Murphy SA; Belardinelli L; Hedgepeth CM; Molhoek P; Verheugt FW; Gersh BJ; McCabe CH; Braunwald E
Circulation; 2007 Oct; 116(15):1647-52. PubMed ID: 17804441
[TBL] [Abstract][Full Text] [Related]
80. One year follow-up of patients with refractory angina pectoris treated with enhanced external counterpulsation.
Pettersson T; Bondesson S; Cojocaru D; Ohlsson O; Wackenfors A; Edvinsson L
BMC Cardiovasc Disord; 2006 Jun; 6():28. PubMed ID: 16776842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
